Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.

ABSTRACT:

Background

Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expression level in patients with glioblastoma multiforme (GBM) undergoing adjuvant radiotherapy (RT).

Methods

We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions) > or = 60 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS).

Results

Patients with weak expression had a bette

SUBMITTER: Chou SY 

PROVIDER: S-EPMC5789739 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature